Interactions between benign prostatic hyperplasia (BPH) and prostate cancer in large prostates: a retrospective data review

Al-Khalil, Shadi; Boothe, David; Durdin, Trey; Sunkara, Sowmya; Watkins, Phillip; Yang, Shengping; Haynes, Allan; Riese, Werner de

doi:10.1007/s11255-015-1146-2

Cited by 31 publications

(30 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…A recent study described an inverse relationship between prostate symptom score and PCa 10. Since a prostate symptom score would correlate with prostate volume, this pattern would be expected when compared with the studies mentioned earlier 2,6–9. However, this study could not show an increase in the accuracy of cancer detection in the multivariate analysis 10.…”

Section: Discussionsupporting

confidence: 39%

“…Several studies have demonstrated a relationship between prostate volume and the incidence of PCa 2,6–9. These studies have shown an inverse relationship between prostate volume and the incidence of PCa; as prostate volume increases, incidence of PCa decreases.…”

Section: Discussionmentioning

confidence: 99%

“…Recent clinical studies have shown that there may be an association between prostate volume and the incidence of PCa 2,6–9. In this context, we performed a study to further elucidate the relationship between prostate volume and the incidence of PCa.…”

Section: Introductionmentioning

confidence: 98%

“…Benign prostatic hyperplasia (BPH) and prostate cancer (PCa) are the most common diseases of the prostate; however, their interaction is not well studied 1,2. Historically, elucidating the epidemiology of BPH has been complicated by the lack of a uniform definition of clinical BPH, quantitative instruments for assessing the severity of lower urinary tract symptoms, and a noninvasive and accurate method for measuring both prostate volume and bladder outlet obstruction.…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

Association of prostate volume with incidence and aggressiveness of prostate cancer

Al-Khalil¹,

Ibilibor²,

Cammack³

et al. 2016

RRU

Self Cite

View full text Add to dashboard Cite

ObjectiveThe aim of this study was to investigate the possible correlation between prostate volume and aggressiveness and incidence of prostate cancer (PCa).Patients and methodsA chart review of a cohort of 448 consecutive prostate biopsy-naive men was performed. These men underwent at least a 12-core biopsy at our institution due to increased prostate-specific antigen serum levels (>4 ng/mL) and/or suspicious findings on digital rectal examination during the period between 2008 and 2013. Transrectal ultrasound was used to determine the prostate volume.ResultsThe positive biopsy rate was 66% for patients with a prostate volume of ≤35 cc and 40% for patients with a prostate volume of ≥65 cc (P<0.001). Of the 110 patients testing positive on biopsy with a volume of ≤35 cc, 10 patients (9.1%) had a Gleason score of ≥8. Of the 27 patients testing positive on biopsy with a volume of ≥65 cc, only 1 patient (3.7%) had a Gleason score of ≥8.ConclusionThese results suggest that there may be an association between prostate volume and the incidence and aggressiveness of PCa. The larger the prostate, the lower the positive biopsy rate for PCa and the lower the Gleason score.

show abstract

Section: Discussionsupporting

confidence: 39%

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 98%

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Association of prostate volume with incidence and aggressiveness of prostate cancer

Al-Khalil¹,

Ibilibor²,

Cammack³

et al. 2016

RRU

Self Cite

View full text Add to dashboard Cite

show abstract

“…An article published in your journal, by Boehm et al concluded that BPH was associated with an increased risk of PCa, however, this increased risk was limited to BPH diagnosed within the previous year and was more evident with respect to low-grade cancers (Gleason score ≤6) [1]. However, our institution has recently presented data showing an inverse correlation between prostate volume, caused by BPH, and the incidence and aggressiveness of PCa [2,3]. Table 1 below displays the breakdown between incidence and aggressiveness of PCa with respect to prostate volume.…”

Section: Dear Editormentioning

confidence: 75%

Association of benign prostatic hyperplasia (BPH) volume and prostate cancer: consecutive data from an academic institution in respect to the current scientific view

Khalil

Riese

2017

World J Urol

Self Cite

View full text Add to dashboard Cite

Identification of the metabolic signatures of prostate cancer by mass spectrometry‐based plasma and urine metabolomics analysis

et al. 2021

The Prostate

View full text Add to dashboard Cite

Objective: Prostate cancer (PCa) is one of the most commonly diagnosed cancers among men which is associated with profound metabolic changes. Systematic analysis of the metabolic alterations and identification of new biomarkers may benefit PCa diagnosis and a deep understanding of the pathological mechanism. The purpose of this study was to determine the metabolic features of PCa.Methods: Plasma and urine metabolites from 89 prostate cancer (PCa) patients, 84 benign prostatic hyperplasia (BPH) patients, and 70 healthy males were analyzed using LC-MS/MS and GC-MS. The Orthogonalised Partial Least Squares Discriminant Analysis (OPLS-DA) was used to find the significantly changed metabolites. The clinical value of the candidate markers was examined by receiver operating characteristic curve analysis and compared with prostate-specific antigen (PSA).Results: Multivariate statistical analyses found a series of altered metabolites, which related to the urea cycle, tricarboxylic acid cycle (TCA), fatty acid metabolism, and the glycine cleavage system. Plasma Glu/Gln showed the highest predictive value (AUC = 0.984) when differentiating PCa patients from healthy controls, with a higher sensitivity than PSA (96.6% vs. 94.4%). Both Glu/Gln and PSA displayed a low specificity when differentiating PCa patients from BPH patients (<53.2%), while the combination of Glu/Gln and PSA can further increase the diagnostic specificity to 66.9%. Conclusions:The present study showed the metabolic features of PCa, provided strong evidence that the amide nitrogen and the energy metabolic pathways could be a valuable source of markers for PCa. Several candidate markers identified in this study were clinically valuable for further assessment.

show abstract

Interactions between benign prostatic hyperplasia (BPH) and prostate cancer in large prostates: a retrospective data review

Cited by 31 publications

References 20 publications

Association of prostate volume with incidence and aggressiveness of prostate cancer

Association of prostate volume with incidence and aggressiveness of prostate cancer

Association of benign prostatic hyperplasia (BPH) volume and prostate cancer: consecutive data from an academic institution in respect to the current scientific view

Identification of the metabolic signatures of prostate cancer by mass spectrometry‐based plasma and urine metabolomics analysis

Contact Info

Product

Resources

About